drugset / Trial / NCT01795209
Ranibizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion in Patients With Fair Vision
Phase 4
Terminated
19 enrolled
Seoul National University Bundang Hospital
Novartis · collabSamsung Medical Center · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
The purpose of this study is to determine the effect of ranibizumab for the treatment of macular edema (ME) secondary to branch retinal vein occlusion (BRVO) in patients with initial fair visual acuity.
Timeline
- Start
- 2013-01
- Primary completion
- 2017-12
- Completion
- 2017-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ranibizumab | Monoclonal antibody | 0.5 mg | Intravitreal |